All the news Showing 10 of 18 articles from: Treatment in chronic infectionGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources New US guidelines recommend screening of all adults for hepatitis C Keith Alcorn / 12 December 2019 All adults in the United States should be screened for hepatitis C by healthcare providers as part of routine medical care, updated guidelines from the American Association for the Study of Liver ... Sofosbuvir/ledipasvir cures most young children with hepatitis C Liz Highleyman / 13 November 2018 Almost all young children ages 3 to 6 years with chronic hepatitis C achieved sustained virological response after 12 weeks of treatment using sofosbuvir/ledipasvir oral granules, according to findings presented at the ... HCV therapy with SVR reduces the risk of several non-liver-related diseases commonly seen in people with chronic HCV Michael Carter / 06 July 2017 The risk of several non-liver complications associated with chronic hepatitis C virus (HCV) infection is reduced after interferon-based treatment that achieves a sustained virological response (SVR), investigators from the United ... Sofosbuvir, daclatasvir and ribavirin cures hepatitis C for most people with advanced cirrhosis or liver transplants Liz Highleyman / 29 April 2015 An interferon-free regimen of sofosbuvir, daclatasvir and ribavirin for 12 weeks produced sustained response rates of 83% for people with hepatitis C virus (HCV) who had advanced liver cirrhosis and 94% for ... Unique 'pay if you clear' proposal for new hepatitis drug BBC / 15 October 2014 Six-week oral treatment can cure hard-to-treat hepatitis C patients Liz Highleyman / 12 March 2014 Interferon- and ribavirin-free treatment using sofosbuvir, ledipasvir and a third direct-acting drug for as little as six weeks can cure most previously untreated people with genotype 1 hepatitis C virus (HCV), including those ... AbbVie Completes Largest Phase III Program of an All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C Genotype 1 AbbVie press release / 31 January 2014 US medical societies launch new hepatitis C treatment guidelines Liz Highleyman / 30 January 2014 The American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA) and International Antiviral Society-USA (IAS-USA) yesterday announced the first new hepatitis C treatment guidelines ... Phase III data show Boehringer Ingelheim’s faldaprevir is effective even in patients with common drug-resistant viral variant Boehringer-Ingelheim press release / 16 December 2013 Simeprevir + sofosbuvir produces high sustained response rates for hard-to-treat patients in COSMOS trial Liz Highleyman / 06 November 2013 A 12-week all-oral combination of simeprevir plus sofosbuvir led to sustained virological response (SVR12) in 93% of genotype 1 prior null responders with mild-to-moderate liver fibrosis, working as well as a longer course ... ← First12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive